A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
about
Gemigliptin: An Update of Its Clinical Use in the Management of Type 2 Diabetes MellitusDipeptidyl peptidase IV inhibitor protects against renal interstitial fibrosis in a mouse model of ureteral obstructionA comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes.A fixed-dose combination tablet of gemigliptin and metformin sustained release has comparable pharmacodynamic, pharmacokinetic, and tolerability profiles to separate tablets in healthy subjectsEffects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials.A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise.Future detection and monitoring of diabetes may entail analysis of both β-cell function and volume: how markers of β-cell loss may assist.Sitagliptin monotherapy has better effect on insulinogenic index than glimepiride monotherapy in Japanese patients with type 2 diabetes mellitus: a 52-week, multicenter, parallel-group randomized controlled trialDifferences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis.Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double-blind randomized controlled trial (INICOM study).Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus.Targeting orphan G protein-coupled receptors for the treatment of diabetes and its complications: C-peptide and GPR146.Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes MellitusGemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry.Gemigliptin: Newer Promising Gliptin for Type 2 Diabetes Mellitus.Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.A multicentre, multinational, randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of gemigliptin (LC15-0444) in patients with type 2 diabetes.Pharmacokinetic Equivalence of the High Dose Strength Fixed-Dose Combination Tablet of Gemigliptin/Metformin Sustained Release (SR) and Individual Component Gemigliptin and Metformin XR Tablets in Healthy SubjectsAbsorption, distribution, metabolism and excretion of gemigliptin, a novel dipeptidyl peptidase IV inhibitor, in rats
P2860
Q28066209-A5FE48B9-6343-45FD-96E3-ED9C2FF7F18AQ28237208-F08C96A9-CFAF-461C-BC43-D2657CF57DF9Q33560279-B181137F-7B92-4B11-8536-FC3BB2EFE1E4Q35072374-CD9081E0-736E-469C-BACB-9AE0E5CBE1F1Q36315963-29A89FDC-F0BE-4D81-A275-138DCEB704F3Q36349300-451395A3-1993-468F-AEF2-21E741D5EA9EQ36402230-5E7D69B2-8907-4085-A6E0-501579DCCEEEQ36625527-080C8C8E-88E6-4910-B21B-08234FBA089CQ38076330-12FAB8F6-7BA0-48C5-8DCF-0C35DCE522A0Q38410754-DA4C4F1A-CB01-4121-8B94-B227986D2D04Q38546981-BB85A04F-6055-4388-8568-029F6A7D3AE6Q38866310-2D65246A-307A-4965-86F6-1C5FE8AB05C5Q42279452-1411896F-5223-4217-8E79-2A260461613FQ43447374-B565FA97-019B-4FD8-82F7-816514FCAC2FQ47137374-426C7246-305F-4544-8A72-382EB4D7A9E7Q51346295-79169572-7E91-4426-A6FB-41DBD0EA773FQ51348627-7E92B28E-B660-443F-95BB-4678A2B84082Q57117936-122C53EE-BA1F-4A62-82C2-45478CB65372Q57151726-4F4F65C5-D5AF-4F44-AC57-C2E1AB7D015F
P2860
A multicenter, randomized, placebo-controlled, double-blind phase II trial evaluating the optimal dose, efficacy and safety of LC 15-0444 in patients with type 2 diabetes.
description
2010 nî lūn-bûn
@nan
2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A multicenter, randomized, pla ...... patients with type 2 diabetes.
@ast
A multicenter, randomized, pla ...... patients with type 2 diabetes.
@en
A multicenter, randomized, pla ...... patients with type 2 diabetes.
@nl
type
label
A multicenter, randomized, pla ...... patients with type 2 diabetes.
@ast
A multicenter, randomized, pla ...... patients with type 2 diabetes.
@en
A multicenter, randomized, pla ...... patients with type 2 diabetes.
@nl
prefLabel
A multicenter, randomized, pla ...... patients with type 2 diabetes.
@ast
A multicenter, randomized, pla ...... patients with type 2 diabetes.
@en
A multicenter, randomized, pla ...... patients with type 2 diabetes.
@nl
P2093
P921
P1476
A multicenter, randomized, pla ...... patients with type 2 diabetes
@en
P2093
P304
P356
10.1111/J.1463-1326.2010.01303.X
P577
2010-12-01T00:00:00Z